1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" provides data on the Idiopathic (Essential) Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables4
List of Figures 5
Introduction 6
Idiopathic (Essential) Hypertension 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Idiopathic (Essential) Hypertension 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials 32
Prominent Drugs 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
C. H. Boehringer Sohn AG and Co. KG 43
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 43
Takeda Pharmaceutical Company Limited 46
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 46
Daiichi Sankyo Company, Limited 48
Clinical Trial Overview of Daiichi Sankyo Company, Limited 48
Merck and Co., Inc. 50
Clinical Trial Overview of Merck and Co., Inc. 50
Medionics International Inc 52
Clinical Trial Overview of Medionics International Inc 52
Bayer AG 54
Clinical Trial Overview of Bayer AG 54
GlaxoSmithKline plc 56
Clinical Trial Overview of GlaxoSmithKline plc 56
Pfizer Inc. 57
Clinical Trial Overview of Pfizer Inc. 57
Les Laboratoires Servier SAS 58
Clinical Trial Overview of Les Laboratoires Servier SAS 58
Clinical Trial Overview of Top Institutes / Government 59
Institut de Recherches Internationales Servier 59
Clinical Trial Overview of Institut de Recherches Internationales Servier 59
Regional Hospital Holstebro 61
Clinical Trial Overview of Regional Hospital Holstebro 61
National Heart, Lung, and Blood Institute 62
Clinical Trial Overview of National Heart, Lung, and Blood Institute 62
University of Erlangen-Nurnberg 63
Clinical Trial Overview of University of Erlangen-Nurnberg 63
University of Pavia 64
Clinical Trial Overview of University of Pavia 64
St. George's University of London 65
Clinical Trial Overview of St. George's University of London 65
Central South University 66
Clinical Trial Overview of Central South University 66
Ehime University Graduate School of Medicine 67
Clinical Trial Overview of Ehime University Graduate School of Medicine 67
Komono Kosei Hospital 68
Clinical Trial Overview of Komono Kosei Hospital 68
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 69
Clinical Trial Overview of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 69
Five Key Clinical Profiles 70
Appendix 111
Abbreviations 111
Definitions 111
Research Methodology 112
Secondary Research 112
About GlobalData 113
Contact Us 113
Disclaimer 113
Source 113

List of Tables
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region, 2014* 7
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Idiopathic (Essential) Hypertension Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Idiopathic (Essential) Hypertension Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Idiopathic (Essential) Hypertension Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 35
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 43
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 46
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 48
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 50
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Medionics International Inc, 2014* 52
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 54
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 56
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 57
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Les Laboratoires Servier SAS, 2014* 58
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut de Recherches Internationales Servier, 2014* 59
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Regional Hospital Holstebro, 2014* 61
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 62
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Erlangen-Nurnberg, 2014* 63
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pavia, 2014* 64
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by St. George's University of London, 2014* 65
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Central South University, 2014* 66
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Ehime University Graduate School of Medicine, 2014* 67
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Komono Kosei Hospital, 2014* 68
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2014* 69

List of Figures
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 112

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hypertension Forecast in 12 Major Markets 2016-2026

Epiomic Epidemiology Series: Hypertension Forecast in 12 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • November 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertension in 12 Major Markets Hypertension (high blood pressure) is a common condition in which the force of the blood against the ...

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Pulmonary ...

Global Hypertension Management Devices Market Research Report 2016

Global Hypertension Management Devices Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Hypertension Management Devices Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Hypertension Management Devices industry, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.